Lijuan Wu
Papers
1
Total Citations
11
H-Index
1
About
Dr. Lijuan Wu is a pioneering researcher at the intersection of artificial intelligence and aging biology, whose work is redefining how we discover therapeutics for longevity. Her primary research areas include AI-driven drug discovery, cellular senescence, and the development of senomorphic agents—compounds that suppress the harmful effects of aging cells without killing them. Dr. Wu’s most notable contribution is her landmark 2024 study, "AI-Driven Robotics Laboratory Identifies Pharmacological TNIK Inhibition as a Potent Senomorphic Agent," which has already garnered 11 citations shortly after publication. In this work, she demonstrated how an automated, AI-powered platform can systematically screen for compounds that target the hallmarks of aging, leading to the identification of TNIK inhibition as a promising strategy to combat cellular senescence. This approach not only accelerates the discovery of dual-purpose therapeutics that address both aging and age-related diseases but also establishes a new paradigm for prioritizing longevity targets. Dr. Wu’s innovative integration of robotics and machine learning positions her at the forefront of geroscience, offering a scalable, data-driven path toward healthier aging.
Research Focus
Key Achievements
Top Papers
- 1